Before a rapid test or reagent ever reaches a field program, it usually has to clear a checkpoint that never appears on the box: WHO Prequalification of In Vitro Diagnostics, known inside procurement circles as PQDx. For a program sourcing validated test kits and reagents, understanding what this checkpoint does — and what it deliberately leaves for the buyer to verify — is the difference between a shortlist that survives an audit and one that does not.
WHO Prequalification of In Vitro Diagnostics is not a marketing claim manufacturers add to a spec sheet. It is a formal WHO assessment, launched in 2010 specifically to give buyers in low- and middle-income countries a way to identify safe, appropriate diagnostics in settings where a national regulatory authority may be thin or absent. For a procurement officer building a shortlist of malaria RDTs, HIV self-tests, or TB assays, the prequalified list functions as a pre-vetted pool: everything on it has already been through a standardized review most field programs have neither the time nor the technical staff to replicate themselves.
What the Prequalification Assessment Actually Checks
The WHO process reviews a manufacturer’s product dossier, evaluates the diagnostic’s performance characteristics, inspects the manufacturing site against international quality management standards such as ISO 13485, and reviews the product’s labeling for accuracy. As of 2026, WHO has moved performance evaluation into a separate prerequisite step that must be completed before the full prequalification assessment begins — tightening, not loosening, the bar. Once a product clears every stage, it is added to the WHO list of prequalified IVDs, and manufacturers take on ongoing post-prequalification obligations: continued compliance, reporting, and surveillance, not a one-time stamp.
Why Two of the Largest Buyers Won’t Purchase Without It
The practical weight of this list comes from who treats it as a gate rather than a suggestion. The Global Fund and the UNICEF Supply Division generally require WHO Prequalification, or approval by a Stringent Regulatory Authority, as a condition of procurement. That single requirement shapes the diagnostics market for entire disease categories: a manufacturer without prequalification is effectively locked out of the largest pooled buyers in global health, regardless of how strong its dossier looks on paper.
What prequalification does not do is finish the buyer’s job. WHO’s own guidance to procurement organizations is explicit that the list is a starting point — programs are still expected to assess a supplier’s financial stability and its actual capacity to deliver the quantities a campaign requires, on the timeline the campaign needs. A prequalified product from a manufacturer that cannot reliably ship at volume is still a procurement risk; the list screens the product, not the relationship.
The Emergency Use Listing Shortcut, and Its Limits
Outbreaks do not wait for a multi-year dossier review, which is why WHO maintains a second, faster pathway: the Emergency Use Listing, or EUL. EUL is a risk-based procedure designed to make unlicensed vaccines, therapeutics, and diagnostics available during public health emergencies, and it replaced the older Emergency Use Assessment and Listing procedure used during the West Africa Ebola outbreak. It has since been used for diagnostics during Ebola, Zika, and COVID-19 responses.
EUL eligibility is narrow by design. The disease has to be serious or immediately life-threatening with real outbreak, epidemic, or pandemic potential, and there has to be no already-licensed product for the indication or the affected subpopulation. The manufacturer still has to operate under a functional quality management system, and critically, has to commit to pursuing full prequalification once the product is licensed. EUL is a bridge, not a permanent substitute for PQDx — a distinction procurement teams should hold onto when an EUL-listed test kit is still on the shelf years after the emergency that justified it has passed.
Three Routes Onto a Procurement Shortlist
| Pathway | When it applies | What it signals to a buyer |
|---|---|---|
| WHO Prequalification (PQDx) | Standard route for an established, licensed diagnostic | Full dossier, performance, site, and labeling review; ongoing surveillance |
| Emergency Use Listing (EUL) | Active public health emergency, no licensed alternative exists | Provisional clearance under a functional QMS, tied to a commitment to seek full PQ later |
| Stringent Regulatory Authority approval | Accepted alternative where the manufacturer holds SRA clearance | Recognized as equivalent evidence by major buyers such as the Global Fund |
What This Means for a Program Building Its Own Shortlist
Since 2010, prequalification has added diagnostics at a modest pace — reporting has put the average at roughly eight new IVDs prequalified per year — concentrated in priority disease areas: HIV rapid tests, self-tests, and viral load assays; malaria RDTs; TB nucleic acid tests; HPV testing; hepatitis B and C and syphilis panels; G6PD deficiency tests; and even certain flow cytometers used in HIV monitoring. That narrow, disease-focused list is a feature of the program, not a gap: it reflects where global procurement volume and outbreak risk are concentrated, not the full universe of diagnostics a field program might eventually need.
For a program without direct access to WHO’s technical review capacity, the practical takeaway is straightforward. Start any diagnostic sourcing decision by checking whether a candidate product is on the WHO prequalified list or has a recognized Stringent Regulatory Authority approval behind it. Treat an EUL listing as time-limited and confirm the manufacturer’s stated pathway to full prequalification. And even after a product clears one of these gates, still verify the supplier’s ability to deliver — because prequalification tells a program a test kit is safe and appropriate to use. It does not tell a program the truck will arrive on time.